Print
Email
Print Edition StoriesWednesday, March 17, 2010
ALS Therapy Institute pairs with N.J. biotech
By Mass High Tech staff
MHT's Julie Donnelly: Biotechs lag in social media use
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Cambridge-based ALS Therapy Institute has teamed up with a New Jersey biotech to test several small-molecule compounds that have the potential to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS), commonly called Lou Gehrig’s disease.
ALS TDI announced the partnership with Aestus Therapeutics Inc. of New Brunswick, N.J., which is working to identify potential therapeutics for ALS. The collaboration is focused on several compounds related to the information Aestus has gained through gene expression profiling and proteomics work.
Aestus uses complex biological data mining techniques to identify therapeutics for screening against targets associated with ALS disease onset or progression.
The potential therapeutics identified will be tested by ALS TDI using a preclinical model of disease. ALS TDI is a nonprofit biotech focused on drug development for ALS. This is the first collaboration between the two biotechs.
ALS is a progressive neurodegenerative disease estimated to affect 30,000 people in the U.S. at any given time.
In February, ALS TDI extended a similar partnership with California Stem Cell Inc. CSC will provide the MotorGraft stem cell line that ALS TDI will use to deliver specific gene expressions to the central nervous system.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
